Phytochemical Name : 6,7-di-O-acetylsinococuline (FK-3000)

Properties Information
PhytoCAT-ID PhytoCAT-602
Phytochemical name or plant extracts 6,7-di-O-acetylsinococuline (FK-3000)
PMID 25823424
Literature evidence These studies demonstrate that FK-3000, isolated from S. delavayi Diels., is a promising, pathway-specific anticancer agent that exhibits low toxicity.
IUPAC name [(1S,9S,12S,13S)-12-acetyloxy-3-hydroxy-4,11-dimethoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,10-tetraen-13-yl] acetate
Phytochemicals’ class or type of plant extracts Alkaloid
Source of phytochemicals or plant Extracts Stephania delavayi
Geographical availability China South-Central, Myanmar
Plant parts NA
Other cancers Breast cancer, Prostate cancer, Colon cancer
Target gene or protein NF-kB, COX-2, cyclin B, p-CDC2
Gene or Protein evidence FK-3000 suppressed NF-kB nuclear translocation, decreased NF-kB phosphorylation, and decreased COX-2 protein expression. Conclusively FK-3000 exerts its antiproliferative effect through two pathways: i) G2/M cell cycle arrest via downregulation of cyclin B and phospho-CDC2 by p38 MAPK phosphorylation and CDC25B dephosphorylation, and ii) p38 MAPK-independent induction of apoptosis.
Target pathways NF-kB-COX-2 pathway
IC50 0.52 µg/ml against MDA-MB-231 0.77 µg/ml against MCF-7
Potency The FK-3000 half maximal inhibitory concentration (IC50) in MDA-MB-231 breast carcinoma cells at 48 h was 0.52 µg/ml and it induced apoptosis in a dose- and time-dependent manner.
Cell line/ mice model MDA-MB-231 xenografted mice, MCF-7, MDA-MB-231, PC-3, HT-29
Additional information  The tumor size was smallest in the co-treatment group, indicating that FK-3000 may have a synergistic effect with Taxol. FK-3000 treatment showed no adverse effects on blood cell counts, serum protein levels, or pathology.
PubChem ID 9823255
Additional PMIDs 25384584
Additional sources of information https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:581412-1
Safety These studies demonstrate that FK-3000, isolated from S. delavayi Diels., is a promising, pathway-specific anticancer agent that exhibits low toxicity.